Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Cullinan Therapeutics, Inc. reported a first‑quarter 2026 net loss of $49.661 million as it continued to invest heavily in autoimmune and oncology programs. Research and development expenses were $42.123 million and general and administrative expenses were $11.574 million.
Cash, cash equivalents, and short‑term investments totaled $351.9 million, with an additional $41.4 million in long‑term investments and interest receivable, which management believes can fund operations for at least twelve months. The company remains pre‑revenue and has an accumulated deficit of $637.8 million.
Pipelines advanced meaningfully. The U.S. FDA accepted a new drug application for zipalertinib in EGFR exon 20 insertion non‑small cell lung cancer, with a target action date of February 27, 2027, and a Phase 3 first‑line trial completed enrollment. Early immunology programs, including CLN‑978 and velinotamig, have multiple data readouts planned through 2026. Cullinan also established a $200.0 million at‑the‑market equity offering program to provide additional financing flexibility.
Cullinan Therapeutics reported first quarter 2026 results and highlighted key pipeline milestones in autoimmune disease and oncology. Cash, cash equivalents, investments and interest receivable were $393.3 million as of March 31, 2026, which the company expects will fund operations into 2029 under its current plan.
The company booked a net loss of $49.7 million, with research and development expenses of $42.1 million and general and administrative expenses of $11.6 million for the quarter. Cullinan’s partner-led NDA for zipalertinib in EGFR ex20ins NSCLC was accepted by the U.S. FDA, with a PDUFA target action date of February 27, 2027.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an exercise-and-sell transaction in company stock. She sold a total of 8,000 shares of Common Stock in open-market transactions at weighted average prices of $14.60 and $15.58, with actual trade prices ranging from $14.24 to $15.60. These sales were executed pursuant to a pre-established Rule 10b5-1 trading plan dated August 7, 2025. On the same day, she exercised stock options for 4,000 shares of Common Stock at an exercise price of $4.30 per share, converting a derivative position into additional common shares while using part of her holdings for liquidity.
CGEM-related insider reported proposed sales. The filing lists multiple proposed and completed dispositions of Common stock, including 10b5-1 sales on 03/05/2026 for 8,000 shares at $125,453.60 and an exercise of stock options to sell 4,000 shares on 05/05/2026. The excerpt also shows 4,000 RSUs dated 02/22/2024.
Cullinan Therapeutics, Inc. has registered securities on a Form S-3 shelf and may sell up to $200,000,000 of its common stock through an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen). Sales may occur "from time to time" at market-determined prices under the sales agreement.
The prospectus covers multiple security types but the accompanying base prospectus and sales agreement specifically permit the company to offer common stock with proceeds to be used for general corporate purposes, including R&D, clinical trials, in-licensing and potential acquisitions.
Cullinan Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 16, 2026. The agenda includes electing two Class III directors, Nadim Ahmed and Stephen Webster, to serve until the 2029 annual meeting, ratifying KPMG LLP as independent auditor for 2026, and approving an advisory vote on named executive officer compensation.
The record date is April 20, 2026, with 61,451,380 common shares entitled to vote. The proxy details virtual-only access, board and committee structure, director pay, and executive pay, including 2025 total compensation of $5,100,006 for CEO Nadim Ahmed, $2,221,578 for CMO Jeffrey Jones, and $2,078,837 for CFO Mary Kay Fenton.
Cullinan Therapeutics Inc ownership update: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock as of the amendment filing, following an internal realignment. The filing states on January 12, 2026 certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
Cullinan Therapeutics, Inc. files its annual report describing an expanded pipeline in autoimmune disease and oncology and its collaboration strategy. The company highlights CLN-978, a CD19xCD3 T cell engager in Phase 1 trials for lupus, rheumatoid arthritis and Sjögren’s disease, and velinotamig, a BCMAxCD3 engager licensed from Genrix for plasma cell–driven autoimmune conditions.
In oncology, CLN-049, a FLT3xCD3 T cell engager for AML and MDS, has Phase 1 data showing complete response plus partial hematologic recovery rates up to 31% at certain doses and has Fast Track designation. Zipalertinib, partnered with Taiho, has pivotal REZILIENT1 data in EGFR exon 20 insertion NSCLC, supporting a completed rolling NDA submission for accelerated approval and a global Phase 3 first-line trial now fully enrolled. The company also outlines substantial potential milestone and profit‑share economics from Taiho and details key licensing agreements and an IP estate with patents extending into the 2040s.
Cullinan Therapeutics reported a full-year 2025 net loss attributable to the company of $219.9 million, compared with $167.4 million in 2024, driven mainly by higher research and development spending. Cash, equivalents, investments and interest receivable totaled $439.0 million as of December 31, 2025, which the company expects will fund operations into 2029.
The company highlighted multiple 2026 milestones, including initial clinical data for CLN-978 in systemic lupus erythematosus and rheumatoid arthritis in Q2 2026 and repeat dosing data in Q3 2026. Partner Taiho completed a rolling NDA submission and enrollment of the REZILIENT3 frontline study for zipalertinib, while Cullinan plans to advance CLN-049 toward registrational development in acute myeloid leukemia.